Primary Nocturnal Enuresis
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Ferring PharmaceuticalsArgentina - Buenos Aires
2 programs1
1
MINIRIN Oral LyophilisatePhase 41 trial
desmopressinPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsMINIRIN Oral Lyophilisate
Ferring Pharmaceuticalsdesmopressin
Clinical Trials (2)
Total enrollment: 353 patients across 2 trials
A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)
Start: Dec 2004Est. completion: Sep 2005221 patients
Phase 4Completed
Desmopressin Response in the Young
Start: Jul 2004Est. completion: Feb 2006132 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space